Wellorithm Semaglutide Review

Wellorithm—found at wellorithm.com, based in Miami, Florida—is a newer cash-pay GLP-1 telehealth service with more published operational detail than most 2026 launches, wrapped in marketing claims that need reading skeptically. Our research (checked July 25, 2026) verified both.

The Menu: Injectable and Oral, Compounded and Brand

Verified from Wellorithm's pages, with a "$100 off your first month" promotion running:

• Compounded semaglutide—injection or oral dissolving tablets, from $147/month
• Compounded tirzepatide—injection or oral tablets, from $249/month
• Brand-name: Wegovy® from $899, Zepbound® from $1,199, Ozempic® from $1,199, Mounjaro® from $1,399
• NAD+ and sermorelin—from $150

Oral tablet options for both semaglutide and tirzepatide are still uncommon; offering them alongside four brand-name pathways gives Wellorithm one of the fuller menus among newer services. Plans include unlimited appointments, messaging, and 24/7 support with no membership fees, free fast shipping, and HSA/FSA eligibility.

Named Physicians and Real Contact Details

Wellorithm names its physicians—Dr. Ana Lisa Carr, MD and Dr. Kelly Tenbrink, MD (the same independent medical network serving BreezeMeds and Sunlight in our rankings) plus Dr. David Mansour, DO (board-certified in emergency medicine)—and publishes a Miami address (7931 NW 68th Street, Miami, FL 33166), phone ((877) 402-6778), and email. A LegitScript badge is displayed. Coverage is 49 states—Louisiana excluded.

Read the Marketing Skeptically

The site's outcome claims outrun the evidence: "6x more weight loss than diet and exercise alone" and an 18% average loss reflect branded-drug trials, not Wellorithm's compounded products; "93% kept the weight off for good" is a company figure at odds with published regain data after GLP-1 discontinuation; and "100,000+ patients" is striking for an April 2026 launch. A "Weight Loss Guarantee" is advertised without published terms—get them in writing, along with refund and cancellation policies, which aren't published either. Its small early Trustpilot record leans positive (pricing, delivery, support praise).

Critical 2026 Regulatory Context

In 2026 the FDA proposed excluding semaglutide and tirzepatide from the 503B bulks list, restricting mass GLP-1 compounding—and the FDA has published concerns about unapproved GLP-1 drugs generally. Confirm current availability; the brand pathways are unaffected.

Important: Compounded Medications

Wellorithm's own disclaimer applies: the FDA has not reviewed these compounded medications for safety, quality, or effectiveness. Consult your own physician before starting.